|Company name||Poseida Therapeutics, Inc.|
NEW YORK, September 1, 2020 – Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Poseida Therapeutics, Inc. (NASDAQ: PSTX) on behalf of Poseida stockholders. Our investigation concerns whether Poseida has violated the federal securities laws and/or engaged in other unlawful business practices.
On or around July 10, 2020, Poseida completed its initial public offering (“IPO”), issuing 14 million shares of common stock priced at $16.00 per share.
Then, on August 18, 2020, Poseida disclosed that the U.S. Food and Drug Administration (“FDA”) had placed a clinical hold on Poseida’s Phase 1 clinical trial evaluating the autologous CAR-T therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer. The FDA placed the hold in order to investigate a patient’s death that occurred in late July.
On this news, Poseida’s stock price fell $3.94 per share, or 30.31%, to close at $9.06 per share on August 18, 2020.
If you purchased or otherwise acquired Poseida Therapeutics shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at email@example.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.